John R. B. Perry

Glycemic and bodyweight effects of GIPR coding variation reflect differences in surface expression and intrinsic functional impairment

The glucose-dependent insulinotropic polypeptide receptor (GIPR) is a major therapeutic target in type 2 diabetes and obesity. Missense variation in GIPR could confer phenotypic effects through alterations to constitutive activity or functional responses to GIP or pharmacological...